

## BENITEC TO ESTABLISH A SPONSORED U.S. ADR PROGRAM

**Sydney Australia, 30 May 2014** Benitec Biopharma Limited (ASX:BLT) is establishing a sponsored Level 1 American Depositary Receipt (ADR) program facility trading in the Over-The-Counter (OTC) market in the United States. Currently, Benitec has an unsponsored ADR program in the U.S.

Benitec has appointed the Bank of New York Mellon (BNYM) as its authorised U.S. representative and Depositary Bank to establish the ADR facility.

The primary benefit of an ADR program is to widen the secondary capital market for Benitec allowing Benitec shares to be traded more easily for U.S. investors. The ADRs will be tradeable via licensed U.S. brokers in the ordinary course of trading in the OTC market in the U.S.

Benitec will release further details on the ADR sponsored program as they become available.

For further information, please contact the persons below, or visit the Benitec website at [www.benitec.com](http://www.benitec.com).

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: <a href="mailto:cstubbings@benitec.com">cstubbings@benitec.com</a>	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: <a href="mailto:jlowe@buchanwe.com.au">jlowe@buchanwe.com.au</a>

### **About Benitec Biopharma Limited:**

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).